Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Arcellx Stock Earns 82 Relative Strength Rating Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024 ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Arcellx Stock Earns Relative Strength Rating Upgrade One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
7 Biotech Stocks to Put on Your Breakthrough Radar Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
